Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
August 12, 2026PamplonaIn recruitment
RMC-6236-304 Phase III Study of Daraxonrasib in Patients with Resected Pancreatic Ductal Adenocarcinoma.
The purpose of this trial is to test an investigational drug called daraxonrasib (RMC-6236). Daraxonrasib is an investigational drug, which means that it has not been approved by the Spanish Agency for Medicines and Health Products (AEMPS) or by any other health authority in any country. Daraxonrasib is currently being investigated in other ongoing studies in pancreatic cancer, and its safety, tolerability, and efficacy are being evaluated in comparison with usual clinical practice. -
August 11, 2026Pamplona/MadridIn recruitment
BNT314-02 Phase I/II, randomized, multicenter clinical trial to investigate the efficacy and safety of BNT314 in combination with pumitamig and chemotherapy in participants with metastatic colorectal cancer.
The main objectives of the study are as follows: Part A (Phase 1, safety run-in, dose escalation): To determine whether BNT314 in combination with pumitamig can be administered safely without causing serious side effects in participants. Part B (Phase 1, dose optimization): To assess whether BNT314 in combination with pumitamig and standard chemotherapy is safe for participants and to determine the appropriate dose of BNT314 to be used in Part C. Part C (Phase 2, randomization versus standard tr... -
August 11, 2026PamplonaIn recruitment
1438-0012 Clinical trial in patients with advanced small cell lung cancer comparing treatment with obrixtamig plus atezolizumab, carboplatin, and etoposide versus standard chemotherapy.
The purpose of this clinical study is to determine whether obrixtamig in combination with atezolizumab, carboplatin, and etoposide (standard chemotherapy) is more effective than standard chemotherapy alone in treating people with advanced small cell lung cancer. -
August 3, 2026PamplonaIn recruitment
CO46096 Cevostamab in combination with pomalidomide and dexamethasone versus standard therapy in previously treated patients with multiple myeloma.
The purpose of this study is to compare the effects, both beneficial and adverse, of cevostamab in combination with pomalidomide and dexamethasone with the standard treatment selected by the study physician—daratumumab in combination with pomalidomide and dexamethasone (DPd), elotuzumab in combination with pomalidomide and dexamethasone (EPd), or carfilzomib in combination with dexamethasone (Kd)—in people with multiple myeloma. -
August 3, 2026PamplonaIn recruitmentEarly phase
95804306EDI1001 A Phase I Study of JNJ-95804306 for Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to help researchers understand whether JNJ-95804306 is safe and effective for treating people with acute myeloid leukemia (AML), myelodysplastic neoplasms (MDS, also known as myelodysplastic syndrome), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL). The study aims to determine a dose—the amount of medication taken at one time—of JNJ-95804306 that can safely and effectively treat AML, MDS, CLL, and SLL. It will also assess the sid... -
August 3, 2026PamplonaIn recruitment
EGL-121 Clinical trial of EGL-001 in adult patients with selected advanced and/or metastatic solid tumors
The main objective of this study is to evaluate the safety and tolerability of EGL-001 in participants with selected advanced and/or metastatic solid tumors whose disease has progressed after previously deriving benefit from standard-of-care treatment with an immune checkpoint inhibitor. -
July 20, 2026Pamplona/MadridIn recruitmentEarly phase
VVD-133214-01 Phase I clinical trial of RO7589831 in participants with advanced solid tumors.
The primary objective of this trial is to determine whether RO7589831 administered at different doses has effects, whether positive or negative, as well as what happens to RO7589831 once it enters the body and how it acts in the body and on your disease. -
July 20, 2026Pamplona/MadridIn recruitment
T3P1001 Phase I/II, open-label clinical trial of T3P-Y058-739, a genetically modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors.
The primary objective of the trial is to determine: the best way to safely administer T3P to patients; the side effects of T3P and how they can be managed; and whether T3P can shrink or control cancers. -
July 19, 2026Pamplona/MadridIn recruitment
79635322MMY3002 Randomized phase III clinical trial comparing JNJ-79635322 with teclistamab in patients with relapsed or refractory multiple myeloma after 1 to 3 prior lines of treatment, including an anti-CD38 antibody and lenalidomide (TRIlogy-5).
The objective of this study is to compare the effects of JNJ-79635322 with those of teclistamab. Teclistamab is already used to treat adults with multiple myeloma. -
July 13, 2026Pamplona/MadridIn recruitment
ZL-1310-003 Phase III, randomized, open-label clinical trial of ZL-1310, a DLL3-targeted antibody-drug conjugate (ADC), compared with investigator’s choice of therapy in participants with relapsed small cell lung cancer.
The objective is to study the samples to understand their responses to the study drug and to obtain more information about small cell lung cancer.